Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans

Century Therapeutics, Inc.

2025-Q1 EPS reported -$0.45 revenue$855,000

Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.
Cash, cash equivalents and marketable securities $249.9M as of March 31, 2024; cash runway into 2026.
Closed $60M private placement led by Bain Capital Life Sciences in April 2024.
Plans additional regulatory filings for CNTY-101 in autoimmune diseases beyond SLE in H2 2024.
FY2024 GAAP operating expense guidance raised to $150-160M (prior $135-145M) due to Clade acquisition and expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Century Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.